ABVX

73.2009.24%
MM

Marc M. P. de Garidel

CEO & Director

Mr. Marc M. P. de Garidel, M.B.A., serves as Director of Claris Biotherapeutics, Inc. and serves as its Chairman of the Board since July 2026. He has been CEO at ABIVAX Société Anonyme since May 5, 2023 and serves as its Director. He had been Interim Chair of the Board of ABIVAX Société Anonyme from May 5, 2023 until July 15, 2024. He had been the Chief Executive Officer of CinCor Pharma, Inc. since July 2021 and had been its Director since May 2021. Mr. de Garidel was Chief Executive Officer of Corvidia Therapeutics, Inc. from January 2018 until August 2020 and serves as President and Director. He served as Chief Executive Officer at AZTherapies, Inc. from September 2020 until April 2021 and served as its Board Member until August 2021. He has served as Vice President at EBE since May 2006. Mr. de Garidel served as the Vice President of the South Region at Amgen International from January 2007 to 2010. He served as Acting President and General Manager at Ipsen Biopharmaceuticals, Inc. Mr. de Garidel was employed at Amgen Inc. in various positions, including Vice President and Chief Administration Officer. He served as Vice President of Southwest Europe at Amgen since January 2006. Mr. de Garidel served as the Vice President of Finance & Administration at Amgen Europe from April 1995 to July 1998. He was a Finance Director of Eli Lilly and Company in Germany from 1992 to April 1995. Mr. de Garidel started his career in 1983 with Eli Lilly Pharmaceutical Group. He served as Vice President and General Manager of Amgen France from 2000 to December 2005 and was in charge of general management. Mr. de Garidel served as Vice President of Finance and Corporate Controller of Amgen from 1998 to June 2000. He served as the Chief Accounting Officer of Amgen since December 1998 and Senior Director of Financial Planning & Analysis since July 1998. Mr. de Garidel served as the Chief Executive Officer of Ipsen S.A. from November 22, 2010 to July 18, 2016. He has served as Non-Executive Chairman of Ipsen S.A. since November 22, 2010. He serves as Vice President of the Supervisory Board at Inserm Transfert SA. He served as a Director of Vifor Pharmaceuticals AG from 2015 until May 15, 2018, previously serving as its Director since 2010 and as its Vice Chairman until May 15, 2018. He serves as a Director at TcLand Expression SA and is a Member of the Supervisory Board at Inserm Transfert SA. He served as a Director of Galenica Ltd. since 2015. He served as a Director of Pharnext S.A. since June 2014. Mr. de Garidel holds a Master in Engineering from the École Spéciale des Travaux Publics (Civil Engineering), a Master in International Management from Thunderbird School of Management, Phoenix (USA) and an Executive Master in Business Administration from Harvard University, Boston (USA). He also attended the Advanced Management Program at Harvard Business School.

Positions